The Efficacy of the Low-FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) Diet in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

• Published in: Curēus (Palo Alto, CA) Vol. 17; no. 1; p. e77053
• Main Authors: Khan, Zahid, Muhammad, Syed Aun, Amin, Mehul S, Gul, Amresh
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 01.01.2025; Cureus
• Subjects: Bias; Celiac disease; Constipation; Diarrhea; Diet; Endocrinology/Diabetes/Metabolism; Food; Gastroenterology; Inflammatory bowel disease; Intervention; Irritable bowel syndrome; Lactose; Medical research; Medical Subject Headings-MeSH; Meta-analysis; Nutrition; Observational studies; Pathophysiology; Population; Quality of life; Systematic review; general dietary advice; ibs (irritable bowel syndrome); ibs-sss; british dietetic association; low-fodmap diet; high-fodmap diet; irritable bowel syndrome with diarrhea; structural individual low fodmap dietary advice; treatment of irritable bowel syndrome; medical subject headings
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.77053

Irritable bowel syndrome (IBS) is frequently observed in clinical practice and affects people from different parts of the world. The pathogenesis and aetiology are not well-defined or fully understood; however, altered bowel movements, psychological factors, and visceral hypersensitivity may contribute to symptoms via a pathway mediated by serotonin and other enteric neurotransmitters. Altered bowel movements, including diarrhoea and constipation, abdominal pain relieved by passing flatus, and bloating are the main salient features of this condition. This systematic review and meta-analysis aimed to determine the effectiveness and efficacy of a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP) diet in these patients. Systematic searches were conducted on PubMed, Medline, Google Scholar, and Cochrane Library. Randomised controlled trials (RCTs), systematic trials and cohort studies that included keywords about IBS and a low-FODMAP diet were included. Exclusion criteria included studies that were not in the English language, not relevant to IBS, diet-related to inflammatory bowel disease, or not pertinent to the subject. A total of 41 studies were included in this systematic review and meta-analysis. There was significant heterogeneity among the RCTs; hence, a random-effects model was used. The systematic review included a total of 8460 patients across 36 studies, with follow-up durations ranging from 11 to 16 months. Specifically, the meta-analysis included 15 RCTs with 1118 participants and follow-up durations from two days to nine weeks and six cohort studies including 292 patients with follow-up durations from two weeks to two years. The risk ratio (RR) was 1.21 (95% confidence interval= 0.98-1.51), and the I value ​​​​​was 63% for global symptom improvement with a low-FODMAP diet using a random-effects model. There was a low risk of bias in the RCTs. Five studies were included evaluating the effect of a low-FODMAP diet on quality of life, and these studies did not show any statistically significant benefit of a low-FODMAP diet on quality of life, although a mean difference of 4.59 (95% CI 1.50-7.67) was observed. The risk of bias was moderate to severe in the observational studies included in this review. Food intolerance is increasingly recognised as a contributory factor in IBS, and its role in the pathogenesis and precipitation of symptoms is being explored. Specific mechanisms include the fermentation of FODMAPs by the gut microbiota, leading to gas production and subsequent symptoms.